EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients

NCT02117375 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2020-06-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the prognostic value of early focal lesions and early diffuse lesions on ambulatory disability progression within 5 years after clinical onset.

Conditions

Interventions

DEVICE

spinal cord MRI follow-up

Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio

OTHER

clinical follow-up

Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty

OTHER

brain MRI follow-up

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Gilles GE Edan · CHU Rennes

  • Bruno BB Brochet · University Hospital, Bordeaux

  • Thibault TM Moreau · CHU Dijon

  • Sandra SV Vukusic · Hospices civils Lyon

  • Jean JP Pelletier · AP-HM

  • Marc MD Debouverie · CHU NANCY

  • Bruno BS Stankoff · Pitié Salpêtrière

  • Ayman AT Tourbah · CHU REIMS

  • Jérôme JD De Seze · CHU Strasbourg

  • David DB Brassat · University Hospital, Toulouse

  • Pierre PL Labauge · University Hospital, Montpellier

  • Thibaut TM Moreau · University Hospital, Clermont-Ferrand

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2022-04-30
Completion
2022-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02117375 on ClinicalTrials.gov